NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
NCT ID: NCT01816048
Last Updated: 2019-12-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
8 participants
INTERVENTIONAL
2013-05-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAK-700
TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.
The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time.
TAK-700
TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
Fluorine F 18 Sodium Fluoride
Undergo NaF F18 PET/CT scan
Positron Emission Tomography
Undergo 18F NaF PET/CT scan
Computed Tomography
Undergo 18F NaF PET/CT scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-700
TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
Fluorine F 18 Sodium Fluoride
Undergo NaF F18 PET/CT scan
Positron Emission Tomography
Undergo 18F NaF PET/CT scan
Computed Tomography
Undergo 18F NaF PET/CT scan
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntary written consent
* Histologically proven adenocarcinoma of the prostate
* Evidence of radiographic bone metastases
* May have received prior chemotherapy for metastatic disease, but prior chemotherapy is not a requirement for eligibility
* Eastern Cooperative Oncology Group performance status 0-2
* Serum testosterone level is less than or equal to 50 ng/dL
* Has undergone orchiectomy or plan to continue receiving gonadotropin releasing hormone (GnRH) analogue therapy
* Adequate organ function as measured by screening laboratory values specified in the protocol
* Must agree to use appropriate contraceptives prior to study procedures, during duration of study participation and for 4 months after last dose of TAK 700
* Must be able to lie flat for greater than or equal to 30 minutes during PET/CT imaging
* Screening calculated ejection fraction of greater than or equal to 50% by multigated radionuclide angiography (MUGA) scan or Echocardiogram
Exclusion Criteria
* history of allergic reactions attributed to compounds similar to sodium fluoride F-18 (NaF)
* history of seizure disorder
* Known history of brain metastases
* Concurrent treatment with any herbal products within 7 days of study entry
* Received radiotherapy less than or equal to 4 weeks prior to registration
* Known hypersensitivity to TAK-700 or related compounds
* Prior therapy for treatment of metastatic castrate resistant prostate cancer with any androgen biosynthesis inhibitor or androgen signaling pathway inhibitor such as: enzalutamide (MDV-3100), abiraterone, ketoconazole, or aminoglutethimide
* Current bladder neck outlet obstruction
* Current spinal cord compression
* Current bilateral hydronephrosis
* History of adrenal insufficiency
* History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias (over grade 2), thromboembolic events, or any other cardiac condition within 6 months prior to first dose of study drug.
* Uncontrolled high blood pressure
* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
* Major surgery less than or equal to 4 weeks before the first dose of study drug
* Serious infection less than or equal to 2 weeks before the first dose of study drug
* Known gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of TAK-700, including difficulty swallowing capsules
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Justine Y Bruce, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Wisconsin Carbone Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-1107
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2013-01081
Identifier Type: REGISTRY
Identifier Source: secondary_id
A534260
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH\MEDICINE\HEM-ONC
Identifier Type: OTHER
Identifier Source: secondary_id
CO12810
Identifier Type: -
Identifier Source: org_study_id